Association of monocyte-lymphocyte ratio and proliferative diabetic retinopathy in the U.S. population with type 2 diabetes

Diabetic retinopathy (DR) is a leading cause of blindness, contributing to 2.6% and 1.9% of visual impairment and blindness worldwide [1], respectively in western countries, 33% of patients with diabetes have DR [2]. Early identification of microvascular complication risks provides an opportunity to delay or stop disease onset [3].

Type 2 diabetes is chronic inflammation by increasing insulin resistance and disturbed glucose metabolism. DR as a vascular and neurodegenerative disease occurs after some years of poorly controlled diabetes [4]. Leukocyte activation can cause repeated episodes of capillary occlusion and, progressive retinal ischemia. DR is induced by low grade and persistent leukocyte activation [5]. The upregulation of vascular endothelial growth factor (VEGF) and its receptors is intimately associated with retinopathy progression. VEGF plays a major role in the development of DR [6, 7]. Several biomarkers can reflect the presence of microvascular complications [8] and are also associated with an increased risk of retinopathy [9].

The amount of evidence indicating that several inflammatory markers are associated with an increased risk of DR [10] and that inflammation-related markers play important roles in the prediction and disease assessment of DR has been increasing. The monocyte-lymphocyte ratio (MLR) is a novel inflammatory marker that plays an important role in the prediction and prognosis of some inflammation-related diseases, such as cancer, cardiovascular diseases and DR [11]. Previous studies have shown that white blood cell (WBC) subtypes are closely associated with the inflammatory state of DR [12]. We speculated that MLR may play an important role in the development and progression of DR and be highly significant in PDR patients. However, the association between MLR and PDR remains unclear. Thus, the aim of this study was to explore the clinical and predictive significance of MLR in T2D patients with PDR.

MLR is the monocyte count/lymphocyte count. Both these values can be obtained directly from laboratory data files. The neutrophil count was calculated from the WBC and neutrophil percentages.

The T2D was defined by the American Diabetes Association criteria [13] and a self-report questionnaire. Participants who fulfilled the following criteria were identified as T2D [14]: (1) Glycated hemoglobin (HbA1c) ≥ 6.5%, (2) Fasting plasma glucose (FPG) ≥ 7 mmol/L; (3) during an oral glucose tolerance test, 2-hplasma glucose ≥ 11.1 mmol/L; (4) self-report questionnaire data indicating physician diagnosis of diabetes; and (5) lower blood glucose by current use of insulin or diabetes pill.

DR [15] was defined by the presence of hemorrhages, hard exudates, cotton wool spots, microaneurysms, venous beading, intraretinal microvascular abnormalities, and new retinal vessels based on the severity scale of the Early Treatment for Diabetic Retinopathy Study. Non-mydriatic fundus photography (TRC-NW6S; Topcon, Tokyo, Japan) was used to measure the level of retinopathy in the worse eye. The grades were categorized into no DR, non-proliferative DR, and proliferative DR. Detailed information is listed in the Digital Grading Protocol of the NHANES.

Other covariates included sex (male or female), age, race (non-Hispanic white, non-Hispanic Black, Mexican American, other Hispanic, and other), marital status (married, unmarried, and other), body mass index (BMI) (< 25.0, 25.0–29.9 and ≥ 30.0 kg/m²), HbA1C (< 6.5%, ≥ 6.5%), HGB, C-reactive protein (CRP), high-density lipoprotein cholesterol(HDL) and Total cholesterol. Smoking status [14] was categorized as current smokers, former smokers, and never smokers. Participants who had smoked more than 100 cigarettes in the past and reported smoking either some days or every day at the time of the interview were considered to be current smokers, who had smoked more than 100 cigarettes during their lifetime but did not smoke currently were considered former smokers, and who reported not having smoked even 100 cigarettes during their lifetime were considered never smokers. The duration of diabetes was calculated using the reported age at screening minus the age of the subject when they were first informed that they had diabetes. Family history of diabetes was determined using the participant’s answer to the following question: ‘Including those living and deceased, were any of your biological relatives, that is, blood relatives, including grandparents, parents, brothers, and sisters, ever told by a health professional that they had diabetes?’. CRP [16] was quantified by latex-enhanced nephelometry. Respondents with CRP below the lowest sensitivity were assigned to 0.01 or 0.02 mg/dL.

We used the NHANES database to conduct the present study. To our knowledge, our results were the first to show that MLR increased as the incidence of PDR increased. There was a significant correlation between MLR and PDR. The MLR was associated with the prevalence of PDR after other confounding factors were adjusted for. This indicates that MLR might be used to predict the occurrence and progression of PDR.

Increasing amounts of evidence have emerged showing that chronic inflammation plays a dominant role in the development of DR [17]. Grossman et al. pointed out that the WBC, granulocytes, and monocyte levels, not those of lymphocytes, were higher in normoglycemic subjects than in subjects with diabetes [18]. Ji et al. reported that the MLR or lymphocyte to monocyte ratio could mirror the circulating immune status of the host [19]. The MLR level may be more stable than independent monocyte, lymphocyte, and leukocyte levels because of the balance between the monocyte and lymphocyte levels, which is less affected by various physiological and pathological statuses. MLR has been considered a novel inflammatory biomarker as a readily available and inexpensive index calculated by routine blood examination. Therefore, MLR might be a good reflection of the different clinical conditions in patients with DR.

Some studies have suggested that the increase in MLR may be associated with the production of pro-inflammatory chemokines such as interleukin-6 (IL-6, tumor necrosis factor, IL-1β, and monocyte chemotactic protein 1. These chemokines play major roles in the recruitment and activation of monocytes and leukocytes and the subsequent inflammatory responses in patients with DR [10, 20]. Song Yue et al. suggested that higher MLR values may be an independent risk factor for DR [21]. Huang et al. demonstrated that patients with DR patients in the proliferative stage had significantly higher MLRs than those in the non-proliferative stage, and that MLR is a powerful predictor for the occurrence of DR [20]. Our findings are consistent with those of some previous studies. We conducted this study for the first time to our knowledge with a larger sample size in the U.S. population, and focused on the association between MLR and PDR. In the present study, we found that patients with PDR had a remarkably higher MLR than those with NPDR. Because of the enhanced inflammatory response and reduced immune function, a high MLR in patients with PDR may result from an increased number of monocytes and decreased number of lymphocytes. Therefore, our findings suggest that MLR is closely associated with the risk of PDR. The pathogenesis of DR development and progression is complicated, and the role of VEGF in DR is unclear. More studies are needed to determine whether there is a correlation and mutual influence between VEGF and MLR.

Heng Wan et al. revealed that low peripheral blood monocyte levels may be a biomarker for screening at the early stages of DR, but the levels of neutrophils and lymphocytes are not necessarily associated [22]. DR may result in increases in the monocyte levels in the peripheral blood through the attraction and influx of monocytes into the retina by adhering to the outer surface of retinal capillaries and breaking down the blood-retinal barrier [23]. These controversial results may have resulted from the different conditions of the participants, such as subject heterogeneity and lifestyle differences.

This study had some limitations. First, our study is based on data from the NHANES database, making it a cross-sectional study. Even though a relationship between the MLR and the presence of PDR was established, the causal relationship could not be addressed because of the study’s cross-sectional design, further research requires a prospective study. Second, fundus photographs which based on 2-field photography were not a wide-field photography, which may have led us to a misclassification bias and an underestimation of severe DR in the United States. Finally, As some diabetes data were obtained from self-reported recalls, recall and self-reporting bias might occur. Nevertheless, given these limitations, it is essential to design a multi-center-controlled trials to verify our findings.

The aim of the present study was to investigate the relationship between MLR and the occurrence of PDR. The MLR was significantly increased in T2D participants with PDR after adjusting for confounding variables. MLR is a convenient and economical biomarker derived from routine blood examination and may play an important role in follow-up visits in T2D patients. Additional studies are needed to identify the mechanism underlying the association between MLR and PDR.